Pulse Biosciences Inc. 2025年度报告

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of theeffectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Aggregate market value of registrant’s common stock held by non-affiliates of the registrant on March 31, 2026, the last businessday of the registrant’s most recently completed first fiscal quarter, based upon the closing price of the registrant’s common stock onsuch date as reported by Nasdaq Capital Market, was approximately $394,339,817. Shares of voting stock held by each officer and Table of Contents EXPLANATORY NOTE The Company is filing this Amendment No. 1 (“Amendment”) to its Annual Report on Form 10‑K for the fiscal year endedDecember 31, 2025, originally filed with the Securities and Exchange Commission (the “SEC”) on February 19, 2026 (the“Original Filing”), for the purpose of providing the information required by Items 10, 11, 12, 13, and 14 of Part III of Form 10-K.This information was previously omitted from the Original Filing in reliance on General Instruction G(3) to the Annual Report on Pursuant to the rules of the SEC, we have also included as exhibits currently dated certifications required under Section 302of The Sarbanes-Oxley Act of 2002. Because no financial statements are contained within this Amendment, we are not includingcertifications pursuant to Section 906 of The Sarbanes-Oxley Act of 2002. We are amending and refiling Part IV to reflect the In addition, we made certain revisions to the cover page, including the deletion of the reference to our proxy statement. Except as described above, no other changes have been made to the Original Filing. Except as otherwise indicated herein,this Amendment continues to speak as of the date of the Original Filing, and the Company has not updated the disclosures SPECIAL NOTE ABOUT FORWARD-LOOKING STATEMENTS This Amendment contains certain “forward-looking statements” that involve substantial risks and uncertainties. In somecases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,”“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative ofthese terms or other comparable terminology, although not all forward-looking statements contain these words. These statementsrelate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and You should read this Amendment and the documents that we reference elsewhere in this Amendment completely and withthe understanding that our actual results may differ materially from what we expect as expressed or implied by our forward-looking statements. In light of the significant risks and uncertainties to which our forward-looking statements are subject, youshould not place undue reliance on or regard these statements as a representation or warranty by us or any other person that we willachieve our objectives and plans in any specified timeframe, or at all. We discuss many of these risks and uncertainties in greater PART